Buscar en
Revista Colombiana de Cardiología
Toda la web
Inicio Revista Colombiana de Cardiología Relevancia clínica de la interacción clopidogrel y omeprazol: revisión sistem...
Información de la revista
Vol. 19. Núm. 1.
Páginas 25-32 (Enero - Febrero 2012)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 19. Núm. 1.
Páginas 25-32 (Enero - Febrero 2012)
Open Access
Relevancia clínica de la interacción clopidogrel y omeprazol: revisión sistemática
Clinical relevance of clopidogrel and omeprazole interaction: systematic review
Visitas
...
Héctor Holguín1, Mauricio Ceballos1, Pedro Amariles1,
Autor para correspondencia
pamaris@farmacia.udea.edu.co

Correspondencia: Departamento de Farmacia. Universidad de Antioquia. AA 1226. Medellín, Colombia. Tel (574) 2 19 54 60; Fax: (574) 2 19 54 57; Universidad de Antioquia. Calle 67 No. 53-108. Medellín, Colombia.
1 Grupo de investigación Promoción y Prevención Farmacéutica, Universidad de Antioquia. Medellín, Colombia
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Objetivo

realizar una revisión estructurada de la interacción clopidogrel y omeprazol, establecer su relevancia clínica y generar recomendaciones prácticas respecto al tema.

Método

revisión estructurada en PubMed/MedLine de trabajos publicados en los últimos diez años, utilizando como estrategia clopidogrel AND omeprazole. La información se agrupó y complementó acorde con el método utilizado para la cuantificación del efecto y con la determinación de un posible efecto de clase.

Resultados

la búsqueda generó 35 artículos, de ellos se incluyeron 18 (cinco valoraron la interacción in-vitro, seis la interacción in-vivo y diez la interacción como un efecto de clase). Siete estudios reportaron pérdida del efecto antiagregante, mientras que tres no encontraron una alteración relevante del mismo.

Conclusiones

la evidencia de la relevancia clínica de la interacción clopidogrel y omeprazol no es concluyente. Se recomienda seguir las indicaciones de las agencias regulatorias y, en algunos casos, sustituir omeprazol por pantoprazol.

Palabras clave:
antiagregación plaquetaria
clopidogrel
interacción medicamentosa
omeprazol
Objective

to perform a structured review of the clopidogrel and omeprazole interaction, establish its clinical relevance and generate practical recommendations on the subject.

Method

a structured review on PubMedLine of studies published in the last ten years, using clopidogrel AND omeprazole as strategy. The information was grouped and complemented according to the method used to quantify the effect and with the determination of a possible class effect.

Results

the search generated 35 articles, of which 18 were included (five assessed the in-vitro interaction, six the in-vivo interaction and ten analyzed the interaction as a class effect). Seven studies reported loss of the platelet anti-aggregation effect, while three found no significant alteration of the effect.

Conclusions

the evidence of the clinical relevance of clopidogrel and omeprazole interaction is nor conclusive. It is recommended to follow the regulatory agencies indications, and in some cases replace omeprazole for pantoprazole.

Keywords:
platelet anti-aggregation
clopidogrel
drug interaction
omeprazole
El Texto completo está disponible en PDF
Bibliografía
[1.]
P. Pramparo, C. Mendoza, A. Barceló, et al.
Cardiovascular diseases in Latin America and the Caribbean: The present situation.
Prevention and Control, 2 (2006), pp. 149-157
[2.]
P. Toth, A. Armani.
Thienopyridine therapy and risk for cardiovascular events in secondary prevention.
Curr Atheroscler Rep, 11 (2009), pp. 364-370
[3.]
Antithrombotic Trialists’ Collaboration.
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
BMJ, 324 (2002), pp. 71-86
[4.]
S. Mehta, J. Bassand, CURRENT-OASIS 7 Investigators, et al.
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
N Engl J Med, 363 (2010), pp. 930-942
[5.]
D. Bhatt, K. Fox, W. Hacke, et al.
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
N Engl J Med, 354 (2006), pp. 1706-1717
[6.]
R. Ogawa, H. Echizen.
Drug-drug interaction profiles of proton pump inhibitors.
Clin Pharmacokinet, 49 (2010), pp. 509-533
[7.]
G. Hollopeter, H. Jantzen, D. Vincent, et al.
Identification of the platelet ADP receptor targeted by antithrombotic drugs.
Nature, 409 (2001), pp. 202-207
[8.]
P. Savi, J. Pereillo, M. Uzabiaga, et al.
Identification and biological activity of the active metabolite of clopidogrel.
Thromb Haemost, 84 (2000), pp. 891-896
[9.]
Sanofi-Aventis. Plavix prescribing information. Disponible en: http://www.products.sanofi-aventis.us/PLAVIX/PLAVIX.html#PRECAUTIONS.
[10.]
J. Ferreiro, M. Ueno, D. Capodanno.
Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study.
Circ Cardiovasc Interv, 3 (2010), pp. 436-441
[11.]
G. Nogueira, L. Silveira, A. Martin.
Raman spectroscopy study of atherosclerosis in human carotid artery.
J Biomed Opt, 10 (2005), pp. 031117
[12.]
P. Muntner, F. Lee, B. Astor.
Association of high-density lipoprotein cholesterol with coronary heart disease risk across categories of low-density lipoprotein cholesterol: The Atherosclerosis Risk in Communities Study.
Am J Med Sci, 341 (2011), pp. 173-180
[13.]
A. Masood, M. Ali Naqvi, S. Sohail.
In-hospital outcome of acute myocardial infarction in correlation with thrombolysis in myocardial infarction’ risk score.
J Ayub Med Coll Abbottabad, 21 (2009), pp. 24-27
[14.]
Baldominos G. Estudio de efectividad y seguridad de la enoxaparina para la profilaxis de la enfermedad tromboembólica venosa en pacientes hospitalizados por patología médica. Tesis de doctorado. Departamento de Medicina, Universidad de Alcalá; 1992.
[15.]
M. García, C. Coma.
Características estructurales y funcionales de las plaquetas.
Rev Cubana Angiol y Cir Vasc, 1 (2000), pp. 132-141
[16.]
T. Zaidi, L. McIntire, D. Farrell, et al.
Adhesion of platelets to surface-bound fibrinogen under flow.
Blood, 88 (1996), pp. 2967-2972
[17.]
N. Abraham, M. Hlatky, E. Antman, et al.
ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use.
J Am Coll Cardiol, 56 (2010), pp. 2051-2066
[18.]
H. Tran, S. Anand.
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheralarterial disease.
JAMA, 292 (2004), pp. 1867-1870
[19.]
C. Patrono, L. Garcia, R. Landolfi, et al.
Low-dose aspirin for the prevention of atherothrombosis.
N Engl J Med, 353 (2005), pp. 2373-2380
[20.]
CAPRIE Steering Committee.
A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE).
Lancet, 348 (1996), pp. 1329-1330
[21.]
A. Lanas, L. García-Rodríguez, M. Arroyo, et al.
Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants.
Am J Gastroenterol, 102 (2007), pp. 507-515
[22.]
P. Savi, P. Nurden, et al.
Clopidogrel: a review of its mechanism of action.
Platelets, 9 (1998), pp. 251-255
[23.]
Product Information: PLAVIX(R) oral tablets, clopidogrel bisulfate oral tablets. Bristol- Myers Squibb/Sanofi Pharmaceuticals Partnership, Bridgewater, NJ., 2010.
[24.]
P. Savi, J. Pereillo, M. Uzabiaga, et al.
Identification and biological activity of the active metabolite of clopidogrel.
Thromb Haemost, 84 (2000), pp. 891-896
[25.]
M. Kazui, Y. Nishiya, T. Ishizuka, et al.
Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
Drug Metab Dispos, 38 (2010), pp. 92-99
[26.]
J. Mega, S. Close, S. Wiviott, et al.
Cytochrome P-450 polymorphisms and response to clopidogrel.
N Engl J Med, 360 (2009), pp. 354-362
[27.]
D. Roden, C. Stein.
Clopidogrel and the concept of high-risk pharmacokinetics.
Circulation, 119 (2009), pp. 2127-2130
[28.]
A. Shuldiner, J. O’Connell, K. Bliden, et al.
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
JAMA, 302 (2009), pp. 849-857
[29.]
D. Bhatt, B. Cryer, C. Contant, et al.
Clopidogrel with or without omeprazole in coronary artery disease.
N Engl J Med, 363 (2010), pp. 1909-1917
[30.]
D. Bhatt, J. Scheiman, N. Abraham, et al.
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.
J Am Coll Cardiol, 52 (2008), pp. 1502-1517
[31.]
K. Lai, S. Lam, K. Chu, et al.
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.
N Engl J Med, 346 (2002), pp. 2033-2038
[32.]
F. Ng, S. Wong, K. Lam, et al.
Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome.
Am J Gastroenterol, 103 (2008), pp. 865-871
[33.]
S. Shi, U. Klotz.
Proton pump inhibitors: an update of their clinical use and pharmacokinetics.
Eur J Clin Pharmacol, 64 (2008), pp. 935-951
[34.]
Drugs.com: Drug Information OnLine. Clopidogrel [artículo en internet]. Dsiponible en: http://www.drugs.com/pro/clopidogrel.html. [consulta: 03 de noviembre de 2010].
[35.]
H. Blume, F. Donath, A. Warnke, et al.
Pharmacokinetic drug interaction profiles of proton pump inhibitors.
Drug Saf, 29 (2006), pp. 769-784
[36.]
P. Amariles, N. Giraldo, M. Faus.
Interacciones medicamentosas en pacientes infectados con el VIH: aproximación para establecer y evaluar su relevancia clínica.
Farm Hosp, 3 (2007), pp. 283-302
[37.]
European Medicines Agency. Public statement on possible interaction between clopidogrel and proton-pump inhibitors [artículo en internet]. Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf [consulta: 03 de noviembre de 2010].
[38.]
US Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix) [artículo en internet]. Disponible en: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm079520.htm [consulta: 03 de noviembre de 2010].
[39.]
D. Sibbing, T. Morath, J. Stegherr, et al.
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
Thromb Haemost, 101 (2009), pp. 714-719
[40.]
N. Norgard, K. Mathews, G. Wall.
Drug-drug interaction between clopidogrel and the proton pump inhibitors.
Ann Pharmacother, 43 (2009), pp. 1266-1274
[41.]
M. Juhász, L. Herszényi, Z. Tulassay.
Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist.
Digestion, 81 (2010), pp. 10-15
[42.]
O. Oyetayo, R. Talbert.
Proton pump inhibitors and clopidogrel: is it a significant drug interaction?.
Expert Opin Drug Saf, 9 (2010), pp. 593-602
[43.]
M. Gilard, B. Arnaud, J. Cornily, et al.
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study.
J Am Coll Cardiol, 51 (2008), pp. 256-260
[44.]
S. Siriswangvat, N. Sansanayudh, S. Nathisuwan, et al.
Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel.
Circ J, 74 (2010), pp. 2187-2192
[45.]
K. Yun, S. Rhee, H. Park, et al.
Effects of omeprazole on the antiplatelet activity of clopidogrel.
Int Heart J, 51 (2010), pp. 13-16
[46.]
D. Juurlink, T. Gomes, D. Ko, et al.
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
CMAJ, 180 (2009), pp. 713-718
[47.]
M. Zairis, G. Tsiaousis, N. Patsourakos, et al.
The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting.
Can J Cardiol, 26 (2010), pp. e54-e57
[48.]
K. Stockl, L. Le, A. Zakharyan, et al.
Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor.
Arch Intern Med, 170 (2010), pp. 704-710
[49.]
P. Ho, T. Maddox, L. Wang, et al.
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.
JAMA, 301 (2009), pp. 937-944
[50.]
J. Rassen, N. Choudhry, J. Avorn, et al.
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome.
Circulation, 120 (2009), pp. 2322-2329
[51.]
T. Cuisset, C. Frere, J. Quilici, et al.
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.
J Am Coll Cardiol, 54 (2009), pp. 1149-1153
[52.]
H. Neubauer, A. Engelhardt, J. Krüger, et al.
Pantoprazole does not influence the antiplatelet effect of clopidogrel a whole blood aggregometry study after coronary stenting.
J Cardiovasc Pharmacol, 56 (2010), pp. 91-97
[53.]
J. Siller-Matula, A. Spiel, I. Lang, et al.
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.
Am Heart J, 157 (2009), pp. e1-e5
[54.]
S. Kenngott, R. Olze, M. Kollmer, et al.
Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?.
Eur J Med Res, 15 (2010), pp. 220-224
[55.]
D. Juurlink.
Proton pump inhibitors and clopidogrel: putting the interaction in perspective.
Circulation, 120 (2009), pp. 2310-2312
Copyright © 2012. Socidad Colombiana de Cardiología y Cirugía Cardiovascular
Opciones de artículo
Herramientas